Table 1.
Baseline characteristics.
| Cohort characteristics | Totala |
Continued (censored) |
Discontinued |
χ2 (d.f.) | p |
|---|---|---|---|---|---|
|
n = 69 |
n = 24 |
n = 45 |
|||
| n (%) | n (%) | n (%) | |||
| Gender | |||||
| Male | 35 (51) | 13 (37) | 22 (63) | 0.041 (1) | 0.839 |
| Female | 34 (49) | 11 (32) | 23 (68) | ||
| Age (years) | |||||
| 16–25 | 21 (30) | 5 (24) | 16 (76) | 0.169 (2) | 0.919 |
| 26–49 | 32 (46) | 12 (38) | 20 (63) | ||
| ⩾50 | 16 (23) | 7 (44) | 9 (56) | ||
| Ethnicity | |||||
| White | 27 (39) | 11 (41) | 16 (59) | 0.443 (2) | 0.801 |
| Black | 26 (38) | 8 (31) | 18 (69) | ||
| Other | 16 (23) | 5 (31) | 11 (69) | ||
| Diagnosis | |||||
| Schizophrenia | 34 (49) | 11 (32) | 23 (68) | 5.492 (3) | 0.139 |
| Schizoaffective disorder | 12 (17) | 2 (17) | 10 (83) | ||
| Bipolar affective disorder | 18 (26) | 7 (39) | 11 (61) | ||
| Other | 5 (7) | 4 (80) | 1 (20) | ||
| Duration of illness (years) | |||||
| 0–4 | 35 (51) | 12 (34) | 23 (66) | 3.373 (2) | 0.185 |
| 5–9 | 15 (22) | 4 (27) | 11 (73) | ||
| ≥10 | 19 (28) | 8 (42) | 11 (58) | ||
| Care setting at initiation | |||||
| Inpatient | 47 (68) | 15 (32) | 32 (68) | 0.091 (1) | 0.763 |
| Outpatient | 22 (32) | 9 (41) | 13 (59) | ||
| Previous clozapine trial | |||||
| Yes | 23 (33) | 7 (30) | 16 (70) | 1.359 (1) | 0.244 |
| No | 46 (67) | 17 (37) | 29 (63) | ||
| Treatment resistance | |||||
| Yes | 33 (48) | 8 (24) | 25 (76) | 4.594 (1) | 0.033 |
| No | 36 (52) | 16 (44) | 20 (56) | ||
| No. of previous antipsychotics | |||||
| 0–2 | 25 (36) | 13 (52) | 12 (48) | 7.527 (1) | 0.006 |
| >2 | 44 (64) | 11 (25) | 33 (75) | ||
| Started for clozapine augmentation | |||||
| Yes | 7 (10) | 4 (57) | 3 (43) | 0.484 (1) | 0.487 |
| No | 62 (90) | 20 (32) | 42 (68) |
a
Distributions within the total group are shown as column percentages.